A research team managed to force cancer cells to turn into fat cells in a new test on mice.
To get the result, the team exploited abnormal behavior of the same metastatic cells as breast cancer. The results are truly promising.
When you cut your finger, or when the organs of a fetus grow, the epithelial cells begin to become more “fluid”. They transform into a type of cell called mesenchymal, and then into the type of cell needed at that time.
This process is called epithelial-mesenchymal transition (EMT). It has been known for some time that cancer adopts both this process and its opposite, the mesenchymal-epithelial transition, to spread throughout the body.
The researchers treated mice affected by aggressive breast cancer with two drugs. One for diabetes called rosiglitazone, another for cancer called trametinib.
The use of these drugs caused the cancer's systems to go haywire and it began to transform its cells into fat cells in a process called adipogenesis.
In a paper from last January, the team had presented its theoretical model.
Today's results essentially convey two news items, one very good and one not too bad. The first (not too bad) is that almost all, but not all cancerous cells turn into fat. The tests will have to ascertain the dosages and times of the procedures, and the team is already working on this (also investigating other types of cancer that can be tackled with this method).
The very good news is that in this case the adipogenesis process is irreversible. If it will work for all cells we will find ourselves going from one cancer a little fat to get rid of.
“Breast cancer cells subjected to treatment not only become fat cells, but more importantly they stop proliferating,” says Gerhard Christofori, the biochemist from the University of Basel in Switzerland, first author of the research.
The interesting thing is that the two drugs are already approved by the Food and Drug Administration: for this reason the passage to clinical tests on human beings will be very simple and rapid.
“In the future, this innovative therapeutic approach could be used in combination with conventional chemotherapy to suppress both the tumor and its possible metastases,” explains Christofori.
The research was published and resumed in the journal Cancer Cell.
